Idex Corp. price target raised to $250 from $225 at Argus

Argus raised the firm’s price target on Idex Corp. to $250 from $225 and keeps a Buy rating on the shares after its Q2 earnings beat. The company has a long record of dividend growth and industry outperformance and also looks well positioned for the future, the analyst tells investors in a research note. Shares are down from 52-week highs as orders growth has slowed in the Health & Science segment due to satisfactory inventory levels, but this is a temporary issue, and Idex’s secular growth is likely to resume, the firm added.